CON

ANALYST NOTE: CONCENTRA GROUP HOLDINGS PARENT, INC. (CON) DATE: 2026-06-13 SUBJECT: Structural Setup & Business Fundamentals Review

1. Structural Readiness

Setup State: Forming Conservative Entry: — (Not yet triggered; requires a close above the breakout level) Current Price: $28.56 Extension: — (Not applicable; price has not yet broken out to measure extension) Breakout Level: — (Not yet established; requires price action to define the resistance level) ATR Current: 2.6% (Productive; within the historical "sweet spot" of 4–6% volatility, though slightly below the high-volatility threshold, indicating manageable sizing risk) ATR at Breakout: — (Not yet recorded; will be determined at the moment of breakout)

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Thesis Status: None named at this date.

Analysis: As of June 13, 2026, there is no named macro or secular thesis attached to this specific setup. The investment case is strictly tactical, driven by the quality of the price structure (the forming coil) and the immediate fundamental backdrop provided by the Q1 2026 earnings release. We are not assigning a "growth" or "value" label based on external macro narratives but are judging the name solely on the strength of its setup quality and the verifiable business fundamentals reported by management. The conviction weight is derived from the alignment of the technical structure with the recent earnings guidance, not from a pre-existing thematic thesis.

3. Business Fundamentals

Company Overview: Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions, operating as a subsidiary of Select Medical Corporation. The company delivers a comprehensive suite of services including treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific wellness programs.

Business Model & Segments:

• Primary Engine: Workers' compensation is the core driver, accounting for approximately two-thirds of total center revenue.
• Revenue Streams:
• Occupational Health Centers: Stand-alone facilities (632 locations as of March 31, 2026) generating ~93% of revenue.
• Onsite Health Clinics: Employer worksite clinics (411 locations as of March 31, 2026) generating ~5% of revenue.
• Other: Consumer health services and specialized solutions (e.g., Concentra Telemed, Pharmacy, Medical Compliance Administration).
• Customer Base: Patients are generally employed by the company's main customers (employers). As of December 31, 2025, the company partnered with approximately 200,000 employers, including 100% of Fortune 100 companies.

Recent Performance & Guidance (Source: Earnings Transcript, May 8, 2026):

• Revenue Growth: Q1 2026 revenue increased 13.7% year-over-year to $569.6 million, driven by organic volume growth, revenue per visit increases, and acquisitions (Nova Medical Centers and Onsite Innovations).
• Volume & Pricing: Total Volume Per Visit (VPD) increased 6.7% to 54,271. Revenue per visit rose 3.1% to $151.47.
• Guidance Revision: Management has revised 2026 guidance upward:
• Revenue: Increased low/high end by $25 million to a range of $2.275 billion to $2.375 billion.
• Adjusted EBITDA: Increased low/high end by $10 million to a range of $460 million to $480 million.
• Growth Drivers:
• California Rates: A workers' compensation rate increase took effect March 1, 2026, with management anticipating upside to rate growth for the remainder of the year.
• De Novo Expansion: Expecting to open 8–10 new centers in 2026 across Arizona, Idaho, Missouri, Illinois, Virginia, South Carolina, and Florida.
• M&A: Several small bolt-on M&A opportunities are actively underway.
• Balance Sheet: As of March 31, 2026, the company had $434.2 million of availability under its Revolving Credit Facility. Management expects to end the year with leverage comfortably below three times.

4. Archetype & Conviction Stack

Archetype Candidate: Growth Leader / Margin Inflector

• Rationale: The company demonstrates clear top-line growth (13.7% Q1 growth) and margin expansion potential through rate increases (California) and operational leverage from recent acquisitions (Nova, Onsite Innovations). The guidance revision indicates a "margin inflector" dynamic where volume and pricing power are converging to boost EBITDA.
• Valuation Context: The financial spine indicates a forward consensus EPS of $1.52 for FY1 and $1.70 for FY2. Management's expectation to end the year with leverage below 3x suggests a healthy balance sheet relative to earnings power.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. Recent earnings (May 8) and filings (May 7) provide concrete, quantitative data on growth, guidance, and balance sheet strength.
• Rerating Potential: Moderate. The upward revision in guidance and the strong Q1 print provide a fundamental catalyst for a potential multiple expansion if the technical breakout confirms.

ATR Context: The current ATR of 2.6% is "productive" and sits below the "high volatility" (4-6%) sweet spot, suggesting the stock is currently in a lower-volatility consolidation phase typical of a forming coil. This allows for tighter risk management but implies the breakout move may need to be significant to overcome the current volatility compression.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Fundamental: A significant miss on the revised 2026 guidance or a reversal of the California rate upside. A failure to open the planned 8-10 de novo centers would also be a negative signal.

What Would Strengthen:

• Technical: A decisive breakout above the resistance level (breakout level) with volume, confirming the "CONFIRMED-ACTIVE" state.
• Fundamental: Confirmation of the small bolt-on M&A deals or further upward revision of guidance in subsequent quarters. Continued strong performance in the California rate environment.

Gaps in Evidence:

• Breakout Level: The resistance level required for the breakout is not defined.
• Sector/Industry Classification: The specific sector and industry labels are missing from the setup state, though the business description clearly places it in Healthcare/Services.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management revised 2026 revenue guidance up to $2.275B-$2.375B and EBITDA to $460M-$480M; Q1 revenue grew 13.7% to $569.6M driven by volume and pricing; California rate increase took effect March 1, 2026. Sizing hint: Position size should be conservative given the "forming" status and lack of confirmed breakout; treat as a partial setup signal. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).